Plain-English translation of NCT05554939 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called CD19-targeting CAR-γδT cell therapy for patients with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or stopped responding to other treatments. The treatment involves taking immune cells from a donor, editing them in a laboratory to help them find and kill cancer cells, and then infusing them back into the patient. Researchers want to find the right dose of these edited cells and see how safe and effective this treatment is.
Many patients with aggressive lymphoma run out of treatment options when their cancer stops responding to standard chemotherapy and other therapies. This medication represents a newer approach — using the body's own immune system, specially trained in the lab, to fight the cancer — and doctors want to understand if it can help patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In Phase 1, a small group of patients will receive low doses of the edited immune cells first, with careful monitoring to check for side effects; if safe, the dose will be increased in the next group. In Phase 2, more patients will receive the dose found to be safest and most effective. Before receiving the cell infusion, you will receive chemotherapy to prepare your body. You will be closely monitored for at least 28 days after the infusion, and the entire trial will include multiple hospital visits, blood tests, and imaging scans to track how you are responding.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
China